Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.38 |
| ▸ | HTR2C | P28335 | 11/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205104 | 0.81 | HTR2A (0.39) | HTR2AHTR2CL3MBTL1 | |
| SCHEMBL2743214 | 0.79 | HTR2A (0.55) | HTR2AHTR2CL3MBTL1 | |
| SCHEMBL17589233 | 0.79 | HTR2A (0.37) | HTR2AHTR2CJAK2L3MBTL1 | |
| SCHEMBL19733479 | 0.78 | HTR2A (0.40) | HTR2AHTR2CJAK2JAK3USP2 | |
| SCHEMBL21564774 | 0.76 | USP2 (0.50) | HTR2AHTR2CJAK2JAK3USP2 | |
| SCHEMBL16904633 | 0.73 | MCHR1 (0.33) | — | |
| SCHEMBL680295 | 0.72 | L3MBTL3 (0.38) | L3MBTL1 | |
| SCHEMBL26528666 | 0.72 | DRD3 (0.41) | — | |
| SCHEMBL16072934 | 0.71 | PDE10A (0.34) | HTR2AHTR2C | |
| SCHEMBL8235239 | 0.71 | PDE10A (0.34) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233435-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2019-08-01 | — | — | US | disclosed |
| US-10227359-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180222920-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-20180222920-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9834565-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834565-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-9527864-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160075721-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | Incyte Corporporation (US) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227359-B2 | Tricyclic heterocycles as bet protein inhibitors | BRD3, BRD1, BRD2 | HTR2A 2350/4885HTR2C 1496/4885JAK2 1751/4885 |
| US-20190233435-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | HTR2A 2350/4885HTR2C 1496/4885JAK2 1751/4885 |
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | HTR2A 2350/4885HTR2C 1496/4885JAK2 1751/4885 |
| US-20160075721-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | HTR2A 2350/4885HTR2C 1496/4885JAK2 1751/4885 |
| US-20180222920-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | HTR2A 2350/4885HTR2C 1496/4885JAK2 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.